GlassScriptPhysician profile
Aman K Singh
NPI 1548237845
$15,751.84
in general payments reported to CMS, 2019-2025
41 companies · $3,272 in 2025
The $3,272 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $1,315 · 2021: $1,368 · 2022: $2,110 · 2023: $2,808 · 2024: $3,118 · 2025: $3,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,082 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,081.55 |
| Education | $117.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,677.04 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,014.87 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,848.60 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $1,275.51 | 2019-2025 | |
| Genzyme Corporation | $961.95 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $741.71 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $384.75 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $289.54 | 2022-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $284.91 | 2024-2025 | Vowst |
| Madrigal Pharmaceuticals | $271.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $261.04 | 2020-2023 | Avsola, Amjevita |
| Romark Laboratories, Lc | $240.84 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $221.58 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $218.08 | 2019-2024 | Linzess |
| Redhill Biopharma INC. | $215.76 | 2020-2023 | Movantik, Talicia, Aemcolo |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$22,836.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.